血管内皮抑制素联合培美曲塞治疗中晚期非小细胞肺癌68例临床评价

Recombinant Human Endostatin Combined with Pemetrexed for Treating Advanced Non-Small-Cell Lung Cancer in 68 Cases

目的观察重组人血管内皮抑制素联合培美曲塞治疗中晚期非小细胞肺癌的临床疗效。方法选择医院收治的中晚期非小细胞肺癌患者68例,随机分为对照组和观察组,各34例。两组患者均给予培美曲塞化学治疗(简称化疗),观察组患者在此基础上同步给予重组人血管内皮抑制素,3周为1个疗程,两组均治疗2个疗程。在治疗过程中,可根据患者治疗反应给予相应支持治疗。结果治疗后,观察组近期疗效为67.64%,显著高于对照组的50.00%(P<0.05)。治疗结束后,两组患者卡氏生活质量评分(KPS评分)均较治疗前有所下降,但观察组下降程度更小(P<0.05);治疗结束1个月后,两组患者KPS评分均较治疗前有所升高,且观察组改善程度更优(P<0.05)。治疗后,观察组患者的中位进展时间、中位生存期及1年生存率均显著高于对照组(P<0.05)。两组患者总不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素联合培美曲塞治疗中晚期非小细胞肺癌的近期疗效较好,可显著提高患者生存质量,延迟中位进展时间,提高中位生存期及1年生存率,且未显著增加不良反应发生率,值得临床推广。

Objective To discuss the clinical efficacy of human recombinant endostatin combined with pemetrexed in treating middle- late stage non- small cell lung cancer. Methods 68 cases of patients with locally advanced non- small cell lung cancer were randomly divided into control group and observation group, 34 cases in each group. Two groups of patients were given pemetrexed chemotherapy, based on this, the observation group was give human recombinant endostatin, 3 weeks for 1 course of treatment, two groups of patients were treated for 2 courses. In the process of treatment, corresponding support treatment according to the patient re- sponse was given. Results After treatment, the recent curative effect of observation group was 67.64%, which was higher than 50.00% of control group（P 〈 0.05）. KPS score after treatment,two groups of patients was decreased,the drop degree of the observa- tion group was less than the control group,but the group differences were statistically significant（P 〈 0. 05）;1 month after completion of treatment,two groups of patients＇ KPS score was increased,the improvement in the observation group was better than that of control group, the differences were statistically significant（P 〈 O. 05）.After treatment, the observation group of patients in the progress of time,the median survival and a year survival rates were significantly higher than that of control group,the differences were statistically significant（ P 〈 0.05）. The total incidence rate of adverse reactions were similar between the two groups and had no statistical differ- ence（ P 〉 0. 05）. Conclusion The recombinant human endostatin combined with pemetrexed in treating locally advanced non- small cell lung cancer in the near future curative effect is good, can significantly improve the quality of survival, tumor in the progress of time, the median survival and a year survival rate, and on the basis of combination treatment does not significantly increase the inci- dence of adverse reactions,which is worthy of clinical promotion.